A Clinical Study Comparing the Pharmacokinetics and Pharmacodynamic Characteristics of Insulin Degludec Injection (RD15003) and Insulin Degludec Injection (Tresiba®) in Healthy Subjects

NCT05576298 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

46

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes

Interventions

BIOLOGICAL: Insulin degludec injection, RD15003
BIOLOGICAL: Insulin degludec, Tresiba

Sponsor

Sunshine Lake Pharma Co., Ltd.